BR112021020496A2 - Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo - Google Patents

Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo

Info

Publication number
BR112021020496A2
BR112021020496A2 BR112021020496A BR112021020496A BR112021020496A2 BR 112021020496 A2 BR112021020496 A2 BR 112021020496A2 BR 112021020496 A BR112021020496 A BR 112021020496A BR 112021020496 A BR112021020496 A BR 112021020496A BR 112021020496 A2 BR112021020496 A2 BR 112021020496A2
Authority
BR
Brazil
Prior art keywords
nitazoxanide
thiazolides
treatment
oxidative stress
diseases associated
Prior art date
Application number
BR112021020496A
Other languages
English (en)
Inventor
Corinne Foucart
Nicolas Stankovic-Valentin
Peggy Parroche
Robert Walczak
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of BR112021020496A2 publication Critical patent/BR112021020496A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo. a presente invenção se refere a usos inovadores de nitazoxanida ou análogos dos mesmos.
BR112021020496A 2019-04-12 2020-04-09 Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo BR112021020496A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19305480 2019-04-12
PCT/EP2020/060287 WO2020208208A1 (en) 2019-04-12 2020-04-09 Nitazoxanide and thiazolides for use in the treatment of diseases associated with oxidative stress

Publications (1)

Publication Number Publication Date
BR112021020496A2 true BR112021020496A2 (pt) 2021-12-07

Family

ID=66334322

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021020496A BR112021020496A2 (pt) 2019-04-12 2020-04-09 Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo

Country Status (10)

Country Link
US (1) US20220193042A1 (pt)
EP (1) EP3952869A1 (pt)
JP (1) JP2022528727A (pt)
KR (1) KR20210151854A (pt)
CN (1) CN113710247A (pt)
AU (1) AU2020271636A1 (pt)
BR (1) BR112021020496A2 (pt)
CA (1) CA3130518A1 (pt)
MA (1) MA55597A (pt)
WO (1) WO2020208208A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3196479A1 (en) * 2020-11-17 2022-05-27 Philippe Delataille Methods of treatment of liver failure
CN112957358A (zh) * 2021-04-01 2021-06-15 北京大学第三医院（北京大学第三临床医学院） 硝唑尼特及其衍生物在制备预防和治疗骨破坏性疾病药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
EA024063B1 (ru) * 2011-05-16 2016-08-31 Ромарк Лабораториз Л.С. Способ стимуляции иммунного ответа путем введения тиазолидных соединений
US10653678B2 (en) * 2016-04-11 2020-05-19 Genfit Methods of treatment for cholestatic and fibrotic diseases
US10905680B2 (en) * 2016-04-11 2021-02-02 Genfit Methods of treatment for cholestatic and fibrotic diseases
WO2017178174A1 (en) * 2016-04-11 2017-10-19 Genfit Methods of treatment of cholestasis and fibrosis
JP6894923B2 (ja) 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
KR102537043B1 (ko) * 2017-01-27 2023-05-25 장피트 조합 치료요법용 약학 조성물
EP3595656A1 (en) * 2017-03-13 2020-01-22 Genfit Pharmaceutical compositions for combination therapy

Also Published As

Publication number Publication date
WO2020208208A1 (en) 2020-10-15
US20220193042A1 (en) 2022-06-23
CN113710247A (zh) 2021-11-26
EP3952869A1 (en) 2022-02-16
JP2022528727A (ja) 2022-06-15
AU2020271636A1 (en) 2021-11-04
MA55597A (fr) 2022-02-16
CA3130518A1 (en) 2020-10-15
KR20210151854A (ko) 2021-12-14

Similar Documents

Publication Publication Date Title
BR112017018368A2 (pt) composições contendo rna para o tratamento de doenças tumorais
SV2018005610A (es) Derivados de oxopiridina sustituidos
BR112017020149A2 (pt) derivados de maitansinoide, conjugados dos mesmos e métodos de uso
BR112018012707A2 (pt) inibidores da interação de menin-mll
CL2015001756A1 (es) Compuestos derivados de carbamoilpiridona policiclicos; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion de vih en un humano que tiene o se encuentra en riesgo de tener la infeccion.
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
BR112016013832A2 (pt) Uso de análogo e/ou derivado de insulina, formulação farmacêutica e processo para a preparação da mesma, kit e dispositivo médico
CY1124596T1 (el) Φαρμακευτικη συνθεση τραμαδολης για οφθαλμικη χρηση
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
MX2020003803A (es) Composicion de proteinas de guisante que tiene calidad nutricional mejorada.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112021020496A2 (pt) Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo
WO2017151860A8 (en) Human kynureninase enzyme variants having improved pharmacological properties
CO2018008450A2 (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2016000671A1 (es) Construcciones de variantes de sirp-alfa y sus usos
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
BR112018073355A2 (pt) gordura e seus usos médicos
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
CL2023000491A1 (es) Composiciones de erenumab y usos de las mismas (divisional de solicitud n° 02519-2020).
BR112018003455A2 (pt) composição ou composição farmacêutica e uso da composição
BR112017023762A2 (pt) formulações de depósito injetáveis
BR112019009029A2 (pt) anticorpos anti-bag3 em combinação com inibidores do ponto de verificação imune para uso terapeutico